<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-8">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red">
				Eltrombopag in severe aplastic anaemia: liver tests
			</div>


			<div class="content-container">

				<img class="center-img" src="media/images/slide_3-4-3-2/picture1.png" alt="">

				<ul>
					<li><span>Eltrombopag should be discontinued if:</span>
						<ul>
							<li><span>Alanine aminotransferase (ALT) levels increase to ≥3-times the upper limit of normal in patients with normal liver function</span></li>
							<li><span>ALT levels increase to ≥3-times baseline in patients with pre-treatment elevations in transaminases and are any of the following:</span>
								<ul>
									<li><span>Progressive, persistent for ≥4 weeks, accompanied by increased direct bilirubin or by clinical symptoms of liver injury or evidence for hepatic decompensation</span></li>
								</ul>
							</li>
						</ul>
					</li>
				</ul>

			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Eltrombopag in severe aplastic anaemia: liver tests</header>
				
			<ul>
				<li><span>Serum liver tests to be performed include: alanine aminotransferase, aspartate transaminase and bilirubin</span></li>
				<li><span>Serum liver tests should be monitored prior to initiation of eltrombopag, every 2 weeks during the dose-adjustment phase and monthly following establishment of a stable dose</span></li>
				<li><span>Eltrombopag inhibits UGT1A1 and OATP1B1, which may lead to indirect hyperbilirubinaemia</span>
					<ul>
						<li><span>If bilirubin is elevated, fractionation should be performed</span></li>
						<li><span>If abnormal levels are detected, the tests should be repeated within 3–5 days</span></li>
						<li><span>If the abnormalities are confirmed, serum liver tests should be monitored weekly until the abnormality resolves, stabilises or returns to baseline levels</span></li>
					</ul>
				</li>
				<li><span>If the potential benefit for reinitiating treatment with eltrombopag is considered to outweigh the risk for hepatotoxicity, eltrombopag may be reintroduced cautiously and serum liver tests should be measured weekly during the dose-adjustment phase</span></li>
				<li><span>If liver tests abnormalities persist, worsen or recur, eltrombopag should be discontinued permanently</span></li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/Promacta-PI-2014.pdf"><span>GlaxoSmithKline. Promacta (eltrombopag) tablets for oral use. Prescribing Information (draft). 2014</span></li>
			</ul>

		</div>


		

	</div>
</div>